To specifically distinguish the extent to which each component contributes to the targeted siSurv delivery mediated by the PSCA-specific polyplexes, the in vivo anti-tumor effects were directly compared to those obtained with PSCA-specific polyplexes loaded with control siRNA (scFv-mediated PSCA inhibition only) and polyplexes loaded with siSurv but conjugated with a non-specific control antibody (Survivin knockdown only) [26]. This evidence concerns the gene BIRC5 and neoplasm.